Target intelligence / Profile preview

Phosphoinositide-3-kinase regulatory subunit 2 mRNA 3' untranslated region (PIK3R2 mRNA 3' UTR)

Target
PIK3R2 mRNA 3' UTR
Molecular classification
RNA, Untranslated region, Regulatory element
01

Overview

The Phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2) mRNA 3' untranslated region (3' UTR) is a critical regulatory segment of the PIK3R2 transcript, which encodes the p85-beta regulatory subunit of Class IA PI3Ks (UniProt P48567). This region contains multiple binding sites for microRNAs (miRNAs) such as miR-126, miR-497, and miR-135a, which post-transcriptionally regulate PIK3R2 expression by promoting mRNA decay or inhibiting translation (Yuan et al., 2013, PMID: 23563283). In many human malignancies, including breast, lung, and colorectal cancers, the downregulation of these regulatory miRNAs leads to the pathological overexpression of PIK3R2, which in turn constitutively activates the PI3K/Akt/mTOR signaling pathway, driving tumor growth, metastasis, and drug resistance (Wang et al., 2015, PMID: 25605118). Consequently, the PIK3R2 mRNA 3' UTR is considered a significant therapeutic target for RNA-based interventions, including miRNA mimics and antisense oligonucleotides, aimed at restoring normal PI3K signaling. Research indicates that targeting this region can effectively suppress oncogenic phenotypes and sensitize cancer cells to chemotherapy (PubMed 23563283, 25605118).

Other names
PI3K p85-beta mRNA 3' UTRP85B mRNA 3' UTRPhosphatidylinositol 3-kinase regulatory subunit beta mRNA 3' UTRPIK3R2 3'-UTR
02

Mechanism of action

Binding of microRNA mimics or antisense oligonucleotides to specific seed sequences within the 3' UTR triggers the RNA-induced silencing complex (RISC) to mediate mRNA degradation or translational repression, thereby reducing PIK3R2 protein levels and suppressing the PI3K/Akt signaling pathway.

03

Biological functions

Regulation of gene expressionmRNA stabilityTranslational controlSignal transduction regulation
04

Disease associations

CancerBreast cancerColorectal cancerLung cancerGlioblastomaEndometrial cancer
05

Safety considerations

Off-target effects of microRNA-based therapeuticsDelivery vehicle-associated toxicity (e.g., lipid nanoparticles)Potential for innate immune activation by exogenous RNA sequencesCompensatory upregulation of other PI3K regulatory subunits
06

Interacting drugs

miR-126 mimics (experimental)

3 more in the full profile.

07

Biomarkers

PIK3R2 mRNA expression levelsmiR-126 expression levelsPhospho-Akt (p-Akt) levelsPTEN expression status

Beyond the preview

Go deeper on Phosphoinositide-3-kinase regulatory subunit 2 mRNA 3' untranslated region (PIK3R2 mRNA 3' UTR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphoinositide-3-kinase regulatory subunit 2 mRNA 3' untranslated region (PIK3R2 mRNA 3' UTR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call